Triumvira Immunologics, Inc.

Empower cells, change lives.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Austin, TX, USA
  • Currency USD
  • Founded June 2015
  • Employees 17
  • Incorporation Type C-corp
  • Website Triumvira.com

Company Summary

Triumvira's vision is to develop novel T cell therapies that are safer and more efficacious than current cancer treatments (CAR-T, TCR) in liquid and solid tumors. With key R&D/manufacturing in place, the lead candidate, a CD19-directed T cell product (DLBCL), is timed for US/CA Ph I trials in H1-2019. Headquarters in Austin, TX, with R&D located in Hamilton, ON, Triumvira's seasoned management team is led by Dr. Paul Lammers, CEO & President.

Team

  • Paul Lammers
    President and Chief Executive Officer

    Dr. Lammers joined Triumvira in Jan 2018 after completing a 2017 reverse merger for Mirna Therapeutics, where he raised approx $160M and took the company public (NASDAQ). With 30 years in industry, he has served in various Exec/Sr. Mgmt positions in Clinical Development, Medical and Regulatory Affairs including for EMD Serono (Merck KgA) and Organon in the Netherlands (where he received his MD). In the US since 1992, he resides in Austin, TX.

Previous Investors

  • Bloom Burton & Company
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free